A study of panitumumab, oxaliplatin, fluorouracil and l-leucovorine as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer. (PANORAMA study)

A study of panitumumab, oxaliplatin, fluorouracil and l-leucovorine as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer. (PANORAMA study) - A study of panitumumab, oxaliplatin, fluorouracil and l-leucovorine as first-line treatment in patients with KRAS wild-type metastatic colorectal cancer. (PANORAMA study)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005958

Enrollment

Registered

2011-07-11

Start date

2011-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

KRAS wild-type metastatic colorectal cancer

Interventions

FOLFOX+Pmab is repeated every 14 days until meeting the withdrawal criteria.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Histological confirmation of colorectal cancer. 2)Unresectable relapse or metastatic colorectal cancer. 3) Measurable or evaluable disease (RECIST ver.1.1.) 4)KRAS Wild-type 5)No prior chemotherapy except adjuvant chemotherapy if completed more than 6months (L-OHP base: more than 12months) prior to enrollment. 6) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2. 7) Age of 20 years or older. 8) Vital organ functions (listed below) are preserved within 2 weeks prior to entry. i WBC 3,000/mm3 >= and =<12,000/mm3 ii Neurtophils>=1500/mm3 iii Platelets>=100,000/mm3 iv Hemoglobin>=9.0g/dl v AST and ALT =<upper limit of normal (ULN)*2.5 (=<ULN*5 in case of liver metastasis) vi Total bilirubin =<upper limit of normal (ULN)*2.0 vii Serum creatinine =<upper limit of normal (ULN)*1.25 9)Written informed consent.

Exclusion criteria

Exclusion criteria: 1) Peripheral sensory neuropathy (CTCAEv4.0;>=Grade1). 2) Histroy of the serious hypersensitivity for drugs. 3) Active infection. 4) Complications (Evidence of interstinal lung disease, emphysema, pulmonary fibrosis,paralytic or mechanical bowel obstruction, uncontrolled hypertension,uncontrolled diabetes mellitus,cirrhosis, active cardiovascular disease, or past current history (within 3 months) of myocardial infarction, uncontrolled angina pectoris or arrhythmia. 5) Multiple primary cancer within 5years. 6) Need to drain pleural effusion, ascites or pericardial effusion. 7) Uncontrolled diarrhea. 8) Radiological evidence of brain metastasis. 9) Clinically significant mental or psychological disease. 10) Other conditions not suitable for this study.

Design outcomes

Primary

Measure	Time frame
Overall Response Rate	—

Secondary

Measure	Time frame
Progression-free survival Overall Survival Adverse Effect Resection rate of metastatic resion R0 resection rate	—

Countries

Japan

Contacts

Public ContactTakayuki Asao and Soichi Tsutsumi

Gunma University Department of general surgical science

chuchumi@showa.gunma-u.ac.jp027-220-8224

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026